-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Nektar Therapeutics, Raises Price Target to $135

Benzinga·12/16/2025 17:52:32
Listen to the news
HC Wainwright & Co. analyst Arthur He maintains Nektar Therapeutics (NASDAQ:NKTR) with a Buy and raises the price target from $120 to $135.